Scotland First: Babies to be Screened for Muscle-Wasting SMA Condition
Scotland has become the first nation in the United Kingdom to offer routine screening for Spinal Muscular Atrophy (SMA) to all newborns, a move hailed by parents as a potential life-saver for children at risk of the debilitating muscle-wasting disease. The screening, which began this month, is incorporated into the existing newborn blood spot test typically conducted around four days after birth.
SMA, a genetic condition, causes progressive muscle weakness and can lead to significant challenges with breathing, swallowing, and mobility. Early detection is crucial, as treatments are most effective when administered before irreversible muscle damage occurs. On average, three to four babies are born with SMA in Scotland each year.
The decision to implement universal screening follows years of campaigning by families affected by SMA. Tony and Carrie Pearson, whose daughter Grayce was diagnosed with SMA type two at around six months old, have been vocal advocates for a national screening program. “We wish it came out sooner, obviously, but we are grateful now that every other child isn’t going to go through all those issues,” Carrie Pearson told the Press Association. “They’re going to get treatment sooner and be able to meet their milestones, and all families aren’t going to have to go through that anxiety and stress that we did, and other families went through.”
Tony Pearson emphasized the cost-effectiveness of the screening, stating, “It’s £4 to test a baby for SMA. Is a child’s life worth £4? Definitely.” He expressed hope that the rest of the UK would follow Scotland’s lead, calling the initiative a “gamechanger.”
The screening process is being conducted at a laboratory in Glasgow, already equipped to test for ten other disorders. Dr. Sarah Smith, director of the screening laboratory, explained that the goal is to identify babies with SMA before the onset of symptoms. “With SMA, unfortunately, once the symptoms are present, you can’t easily reverse them,” she said. “Our aim is to stop the symptoms from actually happening in the first place. So, we’ll be able to pick up the baby as having SMA pre-symptomatically, and we’ll be able to put them on treatment, and then hopefully they won’t present with some of the symptoms that this disease can have, so they’ll have a much better quality of life.”
The Scottish Government is funding the two-year pilot scheme with £95,000, while pharmaceutical company Novartis is contributing £435,000. Health Secretary Neil Gray stated that the investment demonstrates the government’s commitment to early detection. “SMA can have devastating implications for babies and their families, and this investment demonstrates our commitment to early detection through our screening programme,” Gray said. “By detecting SMA before symptoms develop, screening could allow earlier treatment which could be life-changing and aid secure the best possible care and support for babies and families.”
The move has also garnered support from high-profile figures, including former Little Mix star Jesy Nelson, who disclosed that her twins were diagnosed with SMA and has since become a patron of SMA UK. Giles Lomax, chief executive officer of SMA UK and a father of twins living with SMA, described the Scottish pilot as a “huge moment for the SMA community,” noting that advocates have been campaigning for newborn screening for a decade. He added that with the availability of three treatments through NHS Scotland, the outlook for those diagnosed with SMA has dramatically improved.
Lomax stated, “These babies will now have the opportunity to grow up without lifelong health care needs and the complexity and challenges of living with SMA.”